Nutanixの空売り状況は、投資家がNutanixの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Nutanix (NASDAQ:NTNX) 株価情報, 空売り情報

NUTANIX INC - A

Nutanix

Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data, anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company is into a single operating and reportable segment that is subscription-based business model. Key revenue is generated from United States.

Nutanix Inc

GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) reported fourth-quarter financial results after the market close on Tuesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/03/g44481194/gamestop-reports-fourth-quarter-and-fiscal-year-2024-results">of the report</a>.
Q4 Earnings: GameStop reported fourth-quarter revenue of $1.283 billion, missing the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a> of $1.48 billion. The video game retailer reported fourth-quarter adjusted earnings of 30 cents per share, beating analyst estimates of eight cents per share, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was down about 28% on a year-over-year basis. Hardware and accessories revenue totaled $725.8 million in the quarter, Software revenue came in at $286.2 million and Collectibles revenue reached $270.6 million in the quarter.
GameStop reported fourth-quarter net income of $131.3 million, up from $63.1 million in the prior year&#8217;s quarter. The company ended the period with approximately $4.78 billion in cash, cash equivalents and marketable securities.
GameStop noted in the release that it will not be holding a conference call to discuss its quarterly results. 
Don&#8217;t Miss: <a href="https://www.benzinga.com/general/entertainment/25/03/44428025/netflix-to-launch-first-mmo-video-game-is-it-the-streaming-companys-biggest-gaming-bet-yet">Netflix To Launch First MMO Video Game: Is It The Streaming Company&#8217;s Biggest Gaming Bet Yet?</a>
In a separate <a href="https://www.benzinga.com/pressreleases/25/03/g44481289/gamestop-announces-update-to-its-investment-policy-to-add-bitcoin-as-a-treasury-reserve-asset">press release</a>, GameStop announced its board unanimously approved an update to investment policies to add Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) as a treasury reserve asset.
GameStop shares soared last month following reports the company was considering adding Bitcoin and other crypto assets to its balance sheet. Shares appear to be moving higher after-hours in response to the company&#8217;s strategic move towards crypto.
GameStop previously made a push into the crypto space with the launch of wallets that let users manage crypto and non-fungible tokens (NFTs) and also provided access to GameStop's NFT marketplace. The company closed down the offering in 2023 due to <a href="https://www.benzinga.com/markets/cryptocurrency/23/08/33511904/gamestop-cites-regulatory-uncertainty-drops-ios-chrome-extension-crypto-wallet-support" target="_blank" rel="noreferrer noopener">&#8220;regulatory uncertainty.&#8221;</a>
When GameStop reported third-quarter financial results in December, the company said it was <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36142175/meme-king-ryan-cohen-now-able-to-trade-stocks-with-gamestop-funds" target="_blank" rel="noreferrer noopener">freeing up</a> CEO Ryan Cohen to bet on stocks in order to improve the company&#8217;s financial standing. GameStop did not provide an update on this initiative in its fourth-quarter release.
GME Price Action: <a href="http://benzinga.com/quote/gme" target="_blank" rel="noreferrer noopener">GameStop shares</a> were up 6.50% after-hours, trading at $27.05 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44478334/wall-street-pauses-for-a-breather-miners-rally-as-copper-notches-all-time-highs-whats-driving-markets-tuesday">Wall Street Pauses For A Breather, Miners Rally As Copper Notches All-Time Highs: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Gaming

News

After-Hours Center

Movers

$BTC

GameStop Q4 Earnings: Revenue Miss, EPS Beat, Shares Surge As Board Approves Bitcoin As Treasury Reserve Asset

<ul>
<li>New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting&nbsp;</li>
<li>These data will further add to the already strong clinical data package for EVX-01</li>
<li>The trial remains on track for two-year clinical efficacy data readout in the second half of 2025 &nbsp;</li>
</ul>
COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology&#x2122; powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago April 25-30, 2025. Designed with Evaxion's AI-Immunology&#x2122; platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).
Evaxion will present new biomarker and immune data obtained from the ongoing phase 2 trial. These will further add to EVX-01's already strong clinical data package.

Biotech

General

EVAX

Evaxion To Present New Phase 2 Data For AI-Designed Personalized Cancer Vaccine EVX-01 At AACR 2025 Annual Meeting

ECDA

ECD Auto Design Q3 EPS $(0.08), Revenues $6.4M Up From $5.0M YoY

The smart money or colloquially the whales do things a little differently from everybody else, placing them on loftier ground. One example of this contrast comes courtesy of casino operator Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>). Because of <a href="https://www.benzinga.com/news/25/03/44430061/larry-summers-calls-trump-tariffs-self-inflicted-wound-as-fed-navigates-inflation-worries-policy-is-moving-in-wrong-direction">challenging economic circumstances</a> stemming from inflation to tariffs, it's easy to assume that WYNN stock would be a loser under the present environment. However, the opposite is true, warranting a closer look. To be fair, both from an initial glance and a deeper assessment, WYNN stock would seem a terribly risky long wager. As <a href="https://www.benzinga.com/government/regulations/25/03/44475192/consumer-confidence-falls-to-lowest-since-2022-as-inflation-tariff-worries-grow">a wave of pessimism</a> has swept American households, with the Consumer Confidence Index plunging to its lowest level in over a year. The Trump administration's trade war has compounded ongoing concerns of inflation and equity market volatility, contributing to the dour ambiance.
Nominally, the aforementioned index fell by 7.2 points to 92.9, representing its fourth consecutive monthly decline. Per data released by The Conference Board, it's also the lowest reading since late 2022. Because of the wider implications, the major indices were muted, with the S&amp;P 500 struggling to keep its head above parity.
Under these conditions, one normally wouldn't expect WYNN stock to outperform. Yet on Tuesday, the equity finished the day 1.3% higher. Fundamentally, the counterintuitive move is difficult to explain other than a sentiment divergence. When filtered for income level, all consumer groups expressed deteriorating sentiment except for households earning above $125,000 annually.
It's also possible that particularly young consumers' penchant for travel and experiences may have led to positive vibes for WYNN stock. Still, The Conference Board earlier reported that the number of Americans planning vacations in the next six months <a href="https://www.benzinga.com/25/03/44335131/vacation-planning-hits-15-year-low-in-latest-sign-of-cash-strapped-us-consumer">hit a 15-year low</a>, excluding COVID-19. Therefore, the bullishness in WYNN is an incredibly contrarian move.
<h2 class="wp-block-heading">WYNN Stock Pops from Smart Money Demand</h2>
Despite the rather ugly backdrop that Wynn Resorts finds itself in, two major developments from the smart money have materialized. First, WYNN stock has been a beneficiary of <a href="https://www.benzinga.com/quote/WYNN/insider-trades">insider buys</a> so far this year. Most recently, 10% owner Fertitta Entertainment acquired 1.7 million shares of WYNN, leading to a total transaction of nearly $145.71 million.
When insiders sell shares, such transactions are difficult to decipher accurately as there could be several reasons why, including completely mundane ones. On the other hand, when insiders buy shares, the interpretation is straightforward: they anticipate capital appreciation.
The second catalyst for WYNN stock is that the smart money is moving into the underlying derivatives market. Earlier in the day, Benzinga's <a href="https://www.benzinga.com/insights/options/25/03/44475383/wynn-resorts-unusual-options-activity-for-march-25">options scanner</a> identified unusual activity, with net sentiment leaning optimistically. Interestingly, the most bullish trade was for sold $87 puts with an expiration date of March 28.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="1017" height="277" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25143502/WYNN-unusual-options-activity.jpg" alt="" class="wp-image-841097" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25143502/WYNN-unusual-options-activity.jpg 1017w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25143502/WYNN-unusual-options-activity-300x82.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25143502/WYNN-unusual-options-activity-768x209.jpg 768w" sizes="(max-width: 1017px) 100vw, 1017px" /></figure>
To quickly recap, put holders have the right but not the obligation to sell the underlying security at the listed strike price. On the other end of the trade, put sellers (or writers) receive income for underwriting the risk that the security in question won't fall. If it does fall below the breakeven threshold, put sellers may be obligated to buy the stock, a process known as assignment.
From Tuesday&#8217;s unusual options activity, retail investors may assume that the smart money doesn't see WYNN stock falling materially below $87. Nevertheless, in the worst-case scenario, the smart money is also apparently comfortable owning shares at around $85.35, which is the strike price minus the premium received (or the bid price of $1.65).
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25143029/WYNN-stock-probability-gambit-1024x576.jpg" alt="" class="wp-image-841089" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25143029/WYNN-stock-probability-gambit-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25143029/WYNN-stock-probability-gambit-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25143029/WYNN-stock-probability-gambit-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25143029/WYNN-stock-probability-gambit.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Daring traders can leverage this market intelligence and deploy an aggressive options trade. It must be noted, though, that one of the main risks here is that WYNN stock over the past six years suffers from a negative bias. A long position held for any given eight-week period only has a 45% chance of rising, which isn't great.
Still, not all hope is lost. The nuance is that when WYNN stock encounters modest momentum — such as its current run of 2.5% over the past five sessions — the probabilities of upside tend to be pushed forward to the first few weeks following said momentum.
<h2 class="wp-block-heading">Derivative Wagers for the Aggressive Gambler</h2>
For aggressive traders looking to extract quick profits, the 86/89 bull call spread expiring this Friday may be tempting. This transaction involves buying the $86 call (at a time-of-writing ask of $286) and simultaneously selling the $89 call (at a bid of $82). The proceeds from the short call offset the debit paid for the long call, resulting in a net cash outlay of $204.
In the above trade, the maximum reward is the difference between the strike prices (multiplied by 100 shares) minus the cash outlay or $96. This translates to a payout of a little over 47%, which is triggered should WYNN stock hit the short strike target of $89 at expiration. While the payout isn't the most generous, it's a realistic target given Tuesday's intraday high, which exceeded $89.
Another adventurous trade to consider is the 89/91 bull spread for the options chain expiring April 11. This trade attempts to advantage WYNN's statistical tendency of rising in the early weeks following modest momentum before eventually tapering off. While far riskier, the temptation is that this transaction currently offers a maximum payout of 115%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44479516/23andmes-bankruptcy-sparks-privacy-concerns-over-genetic-database-of-15-million-customers">23andMe&#8217;s Bankruptcy Sparks Privacy Concerns Over Genetic Database Of 15 Million Customers</a></li>
</ul>
Photo: Shutterstock

Equities

Long Ideas

Macro Economic Events

Options

WYNN

Options Corner: The Whales Are Betting Big On Wynn Resorts Despite Slumping Consumer Confidence

Health In Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIT#NASDAQ">HIT</a>), an Insurtech platform company backed by third-party AI technology, is pleased to announce a strategic collaboration with DialCare, a leading provider of telehealth and virtual care solutions. The collaboration aims to enhance access to quality, affordable healthcare by integrating DialCare's virtual primary care and behavioral health services into Health In Tech's dynamic suite of self-funded health plan offerings.
Through this collaboration, Health In Tech will integrate DialCare's services—including virtual primary care, therapy, and psychiatry—into its product offerings, members across the U.S. will benefit from streamlined, on-demand access to licensed providers via phone or video consultations.

Health In Tech Expands Access To Virtual Care Through Collaboration With DialCare; Will Integrate DialCare's Services—including Virtual Primary Care, Therapy, And Psychiatry Into Its Product Offerings

Events

TNGX

Tango Therapeutics To Highlight Preclinical Data On Precision Oncology Pipeline With Five Posters At American Association for Cancer Research Annual Meeting 2025

ORIC

ORIC Pharmaceuticals To Present ORIC-944 Preclinical At AACR 2025 On Apr. 27

Pyxis Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that the Company will present new, positive preclinical data highlighting the potential of micvotabart pelidotin (MICVO, formerly referred to as PYX-201), a first-in-concept antibody-drug conjugate (ADC) that targets EDB+FN, a non-cellular structural component of the tumor extra-cellular matrix. These data will be presented in two poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, held from April 25 to 30, 2025.
"We are thrilled to present new preclinical data at AACR25 that further elucidate the innovative mechanism of action of MICVO, our first-in-concept EDB+FN targeting ADC, which leverages a unique non-cellular mechanism to drive anti-tumor activity," said Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer of Pyxis Oncology. "As we advance MICVO both as a monotherapy and in combination with anti-PD-1 therapy in the clinic, we remain confident in our multi-pronged development strategy in recurrent and metastatic head and neck squamous cell carcinoma where we believe altering the extra-cellular matrix may effectively address a main cause of resistance to other therapies."
In a previous Phase 1 dose escalation study, it was established that MICVO has profound monotherapy effect on multiple tumor types with significant tumor regression. The Company has initiated the Part 2 monotherapy expansion cohorts of the ongoing Phase 1 clinical trial to evaluate MICVO in 2L and 3L recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients who have received prior platinum and PD-1 inhibitor therapy, and 2L and 3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy.
Preliminary data from patients who have received prior platinum and PD-1 inhibitor therapy are expected in the second half of 2025 and preliminary data from patients who have received prior EGFRi and PD-1 inhibitor therapy are expected in the first half of 2026. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck's anti-PD-1 therapy, KEYTRUDA&#xAE;&nbsp;(pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors, with the goal of identifying the recommended Phase 2 dose by mid-year 2025 and a readout of preliminary data in the second half of 2025.
&nbsp;

PYXS

Pyxis Oncology Will Present New Preclinical Data Supporting Development Of First-In-Concept Antibody-Drug Conjugate Targeting EDB+FN In Tumor Microenvironment At AACR 2025

-- Abstract accepted for late-breaking poster presentation –
-- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers --
-- On-track to file an Investigational New Drug (IND) application in 2026 –

ELEV

Elevation Oncology To Present Data For EO-1022 At American Association for Cancer Research Annual Meeting 2025

Pyxis Oncology To Present Preclinical Data On Potential Of PYX-201 At AACR 2025, Apr. 28

CHRS

Coherus To Present Data From Phase 1 Dose Expansion Study Of CHS-114 At 2025 American Association For Cancer Research Annual Meeting

Whales with a lot of money to spend have taken a noticeably bullish stance on Nutrien.
Looking at options history for Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $526,480 and 5, calls, for a total amount of $336,783.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $47.5 and $60.0 for Nutrien, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Nutrien options trades today is 502.29 with a total volume of 3,542.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Nutrien's big money trades within a strike price range of $47.5 to $60.0 over the last 30 days.
<h3>Nutrien Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742934634_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.7</td>
<td>$3.8</td>
<td>$47.50</td>
<td>$456.0K</td>
<td align="right">596</td>
<td>1.2K</td>
</tr>
<tr>
<td>NTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$7.1</td>
<td>$6.6</td>
<td>$6.82</td>
<td>$47.50</td>
<td>$118.6K</td>
<td align="right">826</td>
<td>174</td>
</tr>
<tr>
<td>NTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$2.3</td>
<td>$2.15</td>
<td>$2.3</td>
<td>$50.00</td>
<td>$115.0K</td>
<td align="right">19</td>
<td>601</td>
</tr>
<tr>
<td>NTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$2.65</td>
<td>$2.55</td>
<td>$2.55</td>
<td>$50.00</td>
<td>$40.8K</td>
<td align="right">368</td>
<td>0</td>
</tr>
<tr>
<td>NTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$60.00</td>
<td>$36.0K</td>
<td align="right">304</td>
<td>514</td>
</tr>
</tbody>
</table>

<h3>About Nutrien</h3>
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients - nitrogen, potash, and phosphate - although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in North America and Australia, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Following our analysis of the options activities associated with Nutrien, we pivot to a closer look at the company's own performance.
<h3>Nutrien's Current Market Status</h3>
<ul>
<li>Trading volume stands at 3,690,724, with NTR's price up by 0.32%, positioned at $52.7.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 43 days.</li>
</ul>
<h3>What The Experts Say On Nutrien</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $60.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs downgraded its action to Sell with a price target of $53. 
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Outperform rating on Nutrien, which currently sits at a price target of $62. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $60. 
&#x2A; Maintaining their stance, an analyst from CIBC continues to hold a Outperformer rating for Nutrien, targeting a price of $66. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Nutrien with a target price of $59. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Nutrien, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Markets

This Is What Whales Are Betting On Nutrien

Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Abbott Laboratories.
This isn't normal.
The overall sentiment of these big-money traders is split between 22% bullish and 77%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $659,000, and 2 are calls, for a total amount of $110,995.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $115.0 to $130.0 for Abbott Laboratories over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Abbott Laboratories's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Abbott Laboratories's significant trades, within a strike price range of $115.0 to $130.0, over the past month.
<h3>Abbott Laboratories Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742934628_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.05</td>
<td>$8.4</td>
<td>$8.5</td>
<td>$125.00</td>
<td>$357.0K</td>
<td>2.6K</td>
<td align="right">698</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.55</td>
<td>$8.5</td>
<td>$8.55</td>
<td>$125.00</td>
<td>$74.3K</td>
<td>2.6K</td>
<td align="right">47</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.61</td>
<td>$2.6</td>
<td>$2.61</td>
<td>$125.00</td>
<td>$72.5K</td>
<td>4.7K</td>
<td align="right">97</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.7</td>
<td>$8.6</td>
<td>$8.63</td>
<td>$125.00</td>
<td>$61.1K</td>
<td>2.6K</td>
<td align="right">258</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.29</td>
<td>$1.28</td>
<td>$1.29</td>
<td>$129.00</td>
<td>$56.6K</td>
<td>21</td>
<td align="right">518</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Having examined the options trading patterns of Abbott Laboratories, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Abbott Laboratories</h3>
<ul>
<li>With a volume of 6,176,592, the price of ABT is down -1.27% at $125.6. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 22 days.</li>
</ul>
<h3>Expert Opinions on Abbott Laboratories</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $154.67.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $160. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Abbott Laboratories with a target price of $154. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Abbott Laboratories with a target price of $150. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Abbott Laboratories options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Behind the Scenes of Abbott Laboratories's Latest Options Trends

Financial giants have made a conspicuous bearish move on ZIM Integrated Shipping. Our analysis of options history for ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) revealed 25 unusual trades.
Delving into the details, we found 36% of traders were bullish, while 64% showed bearish tendencies. Out of all the trades we spotted, 18 were puts, with a value of $2,085,419, and 7 were calls, valued at $683,325.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $20.16 for ZIM Integrated Shipping over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of ZIM Integrated Shipping stands at 3193.55, with a total volume reaching 18,096.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in ZIM Integrated Shipping, situated within the strike price corridor from $10.0 to $20.16, throughout the last 30 days.
<h3>ZIM Integrated Shipping Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742934623_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.7</td>
<td>$5.5</td>
<td>$5.7</td>
<td>$20.00</td>
<td>$805.4K</td>
<td>2.1K</td>
<td>2.0K</td>
</tr>
<tr>
<td>ZIM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.45</td>
<td>$4.4</td>
<td>$4.45</td>
<td>$16.66</td>
<td>$246.1K</td>
<td>16.2K</td>
<td>1.2K</td>
</tr>
<tr>
<td>ZIM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.7</td>
<td>$4.3</td>
<td>$4.35</td>
<td>$16.66</td>
<td>$195.3K</td>
<td>16.2K</td>
<td>1.7K</td>
</tr>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.19</td>
<td>$16.66</td>
<td>$187.3K</td>
<td>2.0K</td>
<td>979</td>
</tr>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.15</td>
<td>$16.66</td>
<td>$170.9K</td>
<td>2.0K</td>
<td>1.7K</td>
</tr>
</tbody>
</table>

<h3>About ZIM Integrated Shipping</h3>
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
After a thorough review of the options trading surrounding ZIM Integrated Shipping, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of ZIM Integrated Shipping</h3>
<ul>
<li>Currently trading with a volume of 6,960,387, the ZIM's price is down by -2.56%, now at $15.22. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 56 days.</li>
</ul>
<h3>Expert Opinions on ZIM Integrated Shipping</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $13.67.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on ZIM Integrated Shipping with a target price of $18. 
&#x2A; An analyst from JP Morgan persists with their Underweight rating on ZIM Integrated Shipping, maintaining a target price of $9. 
&#x2A; An analyst from Barclays has decided to maintain their Underweight rating on ZIM Integrated Shipping, which currently sits at a price target of $13. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for ZIM Integrated Shipping, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

ZIM Integrated Shipping Unusual Options Activity

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) has outperformed the market over the past 10 years by 11.17% on an annualized basis producing an average annual return of 21.97%. Currently, First Citizens BancShares has a market capitalization of $25.44 billion. 
Buying $1000 In FCNCA: If an investor had bought $1000 of FCNCA stock 10 years ago, it would be worth $7,302.19 today based on a price of $1880.00 for FCNCA at the time of writing.
<h3>First Citizens BancShares's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742934615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

FCNCA

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

President <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a>&#8216;s&nbsp;nominee to run the <a href="https://www.benzinga.com/topic/social-security">Social Security Administration</a>, Frank Bisignano, was questioned during a Tuesday Senate hearing about customer service improvements, erroneous payments and the potential privatization of the agency.&nbsp;
Bisignano previously served as CEO of Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), when the financial tech company's stock price more than doubled. He was also co-COO at JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) and held other senior positions at Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>). Fortune Magazine <a href="https://fortune.com/2025/01/30/who-is-frank-bisignano-social-security-administration-trump-appointee-first-data-fiserv/">referred </a>to Bisignano&#8217;s &#8220;unmatched record as a crisis manager&#8221; who rebuilt Citigroup's decimated back-office operations after 9/11. 
<h2 class="wp-block-heading">A New Career Path</h2>
Asked where he stood on Elon Musk's efforts via DOGE to cut costs at the agency by firing workers and closing offices, Bisignano replied, &#8220;My objective is to come in and motivate the workforce we have &#8230; to be able to get our job right the first time for the American public.&#8221;
During Tuesday&#8217;s hearing, Bisignano said he plans to use artificial intelligence to identify and weed out fraud, waste and abuse within the system. He repeatedly referred to the current 1% payment error rate, which he says is &#8220;five decimal places too high.&#8221; 
<h2 class="wp-block-heading">Meanwhile, A Growing Crisis At SSA</h2>
The Washington Post <a href="https://www.washingtonpost.com/politics/2025/03/25/social-security-phones-doge-cuts/?utm_campaign=wp_post_most&amp;utm_medium=email&amp;utm_source=newsletter&amp;carta-url=https%3A%2F%2Fs2.washingtonpost.com%2Fcar-ln-tr%2F41c4f66%2F67e2d84d7347ac0732c0908f%2F59728921ae7e8a1cf4aab576%2F11%2F63%2F67e2d84d7347ac0732c0908f">reported</a> Tuesday that the SSA website crashed four times in 10 days this month and the agency is in a deep crisis.
"The federal agency that delivers $1.5 trillion a year in earned benefits to 73 million retired workers, their survivors and poor and disabled Americans is engulfed in crisis, further undermining its ability to provide reliable and quick service to vulnerable customers,&#8221; wrote the outlet. 
Former Labor Secretary <a href="https://in.benzinga.com/topic/robert-reich">Robert Reich</a> contends the SSA is not in crisis because it's running out of money and that raising the cap slightly on income subject to Social Security taxes would put the agency "in good shape forever."
Reich also <a href="https://robertreich.substack.com/p/why-social-security-is-in-the-worst?utm_source=substack&amp;publication_id=365422&amp;post_id=159585835&amp;utm_medium=email&amp;utm_content=share&amp;utm_campaign=email-share&amp;triggerShare=true&amp;isFreemail=true&amp;r=wlhj&amp;triedRedirect=true">says</a> Musk is "dead wrong" in his fraud accusations because "Social Security has a payment accuracy rate of 99.7 percent. None of Musk's businesses comes close to matching that degree of accuracy."
Administrative costs, which Musk has bashed as wasteful, comprise only 0.5%, which Reich says are "the lowest by far of any large program in the public or private sector."
Though Trump swore he'd never touch Social Security, by empowering Musk, who has called the SSA a "Ponzi scheme," some say the buck stops with the president.
"What's going on is the destruction of the agency from the inside out, and it's accelerating," Sen. Angus King (I-Maine) told the Washington Post. "What they're doing now is unconscionable." 
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44479516/23andmes-bankruptcy-sparks-privacy-concerns-over-genetic-database-of-15-million-customers">23andMe&#8217;s Bankruptcy Sparks Privacy Concerns Over Genetic Database Of 15 Million Customers</a></li>
</ul>
Photo: Shutterstock

Government

Politics

Musk's DOGE Vs. SSA: Trump's Nominee Frank Bisignano Tackles Social Security Crisis Amid Privatization Debate

Lumen Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares traded lower Tuesday following reports that AT&amp;T is in talks to acquire the company's <a href="https://www.benzinga.com/quote/LUMN/earnings">consumer fiber business. </a>
What To Know: The potential deal, which is still in negotiations, could be valued at more than $5.5 billion, though terms are not final and talks may still collapse. Neither Lumen nor AT&amp;T has commented about the discussions.
Lumen's stock initially dropped as much as 13% to $4.26 earlier in the day, bringing its market capitalization to approximately $4.4 billion. Meanwhile, AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) shares rose 1.1% to $27.27, giving it a market value of about $196 billion.
At a recent industry conference, Lumen's CFO Chris Stansbury acknowledged the possibility of selling its fiber-to-the-home business, stating the company would not be a consolidator in the increasingly competitive fiber market. He pointed to other major deals in the sector, including Verizon's planned acquisition of Frontier Communications and BCE's agreement to buy Ziply Fiber.
Stansbury noted that bundling fiber and wireless services strengthens large providers by reducing customer churn and increasing pricing power. 
He also confirmed Lumen's fiber unit attracted significant interest from buyers. If a deal is completed, it would likely help Lumen reduce its debt load. Investors appear to be reacting negatively to the uncertainty surrounding the sale and the company&#8217;s longer-term position in the fiber market.
LUMN Price Action: Lumen Technologies shares closed Tuesday down 9.47% at $4.40, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25154634/Screenshot-2025-03-25-at-15.46.08-1024x530.png" alt="" class="wp-image-841209" style="width:437px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25154634/Screenshot-2025-03-25-at-15.46.08-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25154634/Screenshot-2025-03-25-at-15.46.08-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25154634/Screenshot-2025-03-25-at-15.46.08-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/25154634/Screenshot-2025-03-25-at-15.46.08.png 1518w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44478334/wall-street-pauses-for-a-breather-miners-rally-as-copper-notches-all-time-highs-whats-driving-markets-tuesday">Wall Street Pauses For A Breather, Miners Rally As Copper Notches All-Time Highs: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Photo: Courtesy Lumen Inc.

Tech

LUMN

Why Are Lumen Technologies Shares Down Today?

VAUGHAN, ON, March 25, 2025 /CNW/ - GFL Environmental Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GFL#TSX">GFL</a>) ("GFL" or the "Company") today announced that Ontario Teachers' Pension Plan Board, GFL Borrower II (Cayman) LP, Poole Private Capital, LLC, and entities affiliated with HPS Investment Partners, LLC (collectively, the "Selling Shareholders") intend to offer for resale by the underwriters 15,739,769&nbsp;subordinate voting shares (the "Shares"). GFL will not receive any proceeds from the sale of the Shares (the "Offering"). RBC Capital Markets, LLC and RBC Dominion Securities Inc. will act as underwriters for the Offering in the United States and Canada, respectively.
The Shares issued pursuant to the Offering will be offered in all provinces and territories of Canada by way of a prospectus supplement (the "Prospectus Supplement") to the Company's short form base shelf prospectus (the "Base Shelf Prospectus"). The Company has filed a registration statement on Form F-10 (the "Form F-10") and will file the Prospectus Supplement with the U.S. Securities and Exchange Commission (the "SEC") in accordance with the multi-jurisdictional disclosure system established between Canada and the United States.
No securities regulatory authority has either approved or disapproved the contents of this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.
The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible on or about&nbsp;March 27, 2025, through SEDAR+. Prospective investors should read the Base Shelf Prospectus, the Prospectus Supplement, when available, and the documents incorporated by reference therein before investing in the Shares. When available, these documents may be accessed for free on SEDAR+ at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4391228-1&amp;h=1840118248&amp;u=http%3A%2F%2Fwww.sedarplus.ca.%2F&amp;a=www.sedarplus.ca.">www.sedarplus.ca.</a>

Offerings

TSX:GFL

GFL Environmental Announces Secondary Offering Of 15,739,769 Subordinate Voting Shares

The company anticipates using the net proceeds from the offering to fund acquisitions and for working capital and other general corporate purposes.
 &nbsp;

GWRS

Global Water Resources Commences Public Offering Of Shares Of Its Common Stock; No Terms Disclosed

Cryptocurrency markets are trading relatively flat on Tuesday as GameStop announced the acquisition of Bitcoin for its treasury.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$88,471.10</td>
<td>+0.03%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,079.34</td>
<td>-0.6%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$145.94</td>
<td>+2%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.46</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1910</td>
<td>+1.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001376</td>
<td>+0.7%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 78% and daily active addresses growing by 30%. Transactions greater than $100,000 are up from 6,350 to 10,665 in a single day. Exchanges netflows are down by 792.4%.</li>
<li>Coinglass data reports 81,429 traders were liquidated in the past 24 hours for $172.32 million.</li>
<li>Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1904607465934823675">noted</a> that more than 22,000 BTC were withdrawn from exchanges in the past week.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/25/03/44475966/trump-backed-world-liberty-financial-confirms-dollar-stablecoin-plans-with-bitgo">Trump-Backed World Liberty Financial Confirms Dollar Stablecoin Plans With BitGo</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44473477/blackrock-brings-tokenized-money-market-fund-buidl-to-solana">BlackRock Brings Tokenized Money Market Fund &#8216;BUIDL&#8217; To Solana</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44470483/blackrock-expands-bitcoin-etf-offering-to-europe">BlackRock Expands Bitcoin ETF Offering To Europe</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44477525/peter-schiff-says-bitcoin-demand-fueled-by-michael-saylor-speculators-betting-on-strategic-reserve">Peter Schiff Says Bitcoin Demand Fueled By Michael Saylor, Speculators Betting On Strategic Reserve</a></li>
<li><a href="https://www.benzinga.com/25/03/44469596/japan-set-to-welcome-first-legally-backed-dollar-stablecoinfind-out-which-one-it-is">Japan Set To Welcome First Legally-Backed Dollar Stablecoin: Find Out Which One It Is</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44472657/strategy-aims-for-more-bitcoin-with-strife-stock-how-does-it-work">Strategy Aims For More Bitcoin With &#8216;Strife&#8217; Stock: How Does It Work?</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Cronos (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">CRO</a>)</td>
<td>&nbsp;$0.1063</td>
<td>+29.2%</td>
</tr>
<tr>
<td>Movement (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MOVE</a>)</td>
<td>&nbsp;$0.5414</td>
<td>+23.9%</td>
</tr>
<tr>
<td>Zcash (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/zec/usd">ZEC</a>)</td>
<td>&nbsp;$36.68</td>
<td>+14.2%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Altcoin Sherpa predicts a breakout into the low $90,000s, signaling "we're so back," but warns of a potential dump afterward.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">watching <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> closely, seeing if something like this happens. Breakout to low 90ks, &#39;we&#39;re so back&#39; and then dump it <a href="https://t.co/VRYctvWYeM">pic.twitter.com/VRYctvWYeM</a>
&mdash; Altcoin Sherpa (@AltcoinSherpa) <a href="https://twitter.com/AltcoinSherpa/status/1904592319921213698?ref_src=twsrc%5Etfw">March 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Daan Crypto Trades <a href="https://x.com/DaanCrypto/status/1904579281159651543">attributes</a> Bitcoin's recent volatility to stock market movements, noting BTC's strong correlation with the S&amp;P 500 (SPX).
CrypNuevo <a href="https://x.com/CrypNuevo/status/1904594169781465466">highlights</a> Bitcoin's bounce from the 1W 50 EMA, calling it the likely bottom. A full recovery hinges on reclaiming $91,500, though a revisit to $82,000-$81,000 remains possible.
Santiment data shows Bitcoin having surged to around $88,350 after bottoming at around $77,500 two weeks ago. A key factor in the recovery has been whale accumulation, with wallets holding 100–10,000 BTC increasing. As usual, the market improves when whales step back in.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f433;&#x1f4c8; Bitcoin&#39;s price has rallied all the way to ~$88,350 after things looked grim two weeks ago at ~$77,500. Shortly after that local bottom, we began to see a rise in total wallets holding 100 to 10K <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a>. As usual, markets have looked better since whales resumed accumulation. <a href="https://t.co/3zZfyOnCeY">pic.twitter.com/3zZfyOnCeY</a>
&mdash; Santiment (@santimentfeed) <a href="https://twitter.com/santimentfeed/status/1904610453902549041?ref_src=twsrc%5Etfw">March 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Stockmoney Lizards <a href="https://x.com/StockmoneyL/status/1904594847811715500">sees</a> Bitcoin corrections as temporary, calling any price below $80,000 an accumulation opportunity, regardless of how long the recovery takes.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44474962/bitcoin-tests-key-bull-market-support-at-88000-what-does-technical-analysis-say">Bitcoin Tests Key Bull Market Support At $88,000: What Does Technical Analysis Say?</a></li>
</ul>
Image: Shutterstock

$CRO

$DOGE

$ETH

$MOVE

$SHIB

$SOL

$XRP

$ZEC

Bitcoin, Ethereum, XRP, Trade Flat While Dogecoin Moves Up

Press Releases

Nutanix Reports First Quarter Fiscal 2025 Financial Results

Nutanix to Present at Upcoming Investor Conference

Nutanix Announces Proposed $750 Million Convertible Senior Notes Offering

Nutanix Announces Pricing of $750 Million 0.50% Convertible Senior Notes

Rapid GenAI Application Adoption Drives New Era of Application and Infrastructure Modernization

Nutanix Announces Date and Conference Call Information for Second Quarter Fiscal Year 2025 Financial Results

QualityKiosk and DevRev Partner to Enhance Customer Experience and Product Development Through AI-Led Insights

Comments

Nutanix

空売り

Nutanix (NASDAQ:NTNX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル